1.28

0.78% -0.01

After Hours: 1.26 -0.02 -1.56%

Longeveron Inc (LGVN)

Overview News Price History Financials Why LGVN Down? Discussions Forecast

Longeveron Inc stock is currently priced at $1.28, with a 24-hour trading volume of 208.85K. It has seen a -0.78% decreased in the last 24 hours and a -38.76% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.30 pivot point. If it approaches the $1.26 support level, significant changes may occur.

Previous Close:

$1.29

Open:

$1.31

24h Volume:

208.85K

Market Cap:

$8.10M

Revenue:

$709.00K

Net Income/Loss:

$-21.41M

P/E Ratio:

-1.3474

EPS:

-0.95

Net Cash Flow:

$-19.70M

1W Performance:

-12.03%

1M Performance:

-38.76%

6M Performance:

-32.63%

1Y Performance:

-57.89%

1D Range:

$1.2601

$1.32

52W Range:

$0.3313

$5.47

Longeveron Inc Stock (LGVN) Company Profile

Name

Longeveron Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

305 909 0840

Address

1951 NW 7th Avenue, Suite 520, Miami

Employee

Twitter

Next Earnings Date

Latest SEC Filings

LGVN's Discussions on Twitter

Longeveron Inc Stock (LGVN) Latest News

Longeveron Inc. (NASDAQ:LGVN) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Longeveron's (LGVN) Buy Rating Reiterated at HC Wainwright - Defense World

Defense World

Earnings call: Longeveron reports Q1 2024 results, optimistic on Lomecel-B - Investing.com Nigeria

Investing.com Nigeria

Earnings call: Longeveron reports Q1 2024 results, optimistic on Lomecel-B - Investing.com Canada

Investing.com Canada

Earnings call: Longeveron reports Q1 2024 results, optimistic on Lomecel-B - Investing.com India

Investing.com India

Earnings call: Longeveron reports Q1 2024 results, optimistic on Lomecel-B - Investing.com

Investing.com

Longeveron Inc Stock (LGVN) Financials Data

Longeveron Inc (LGVN) Revenue 2024

LGVN reported a revenue (TTM) of $709.00 thousand for the quarter ending December 31, 2023, a -41.98% decline year-over-year.

Longeveron Inc (LGVN) Net Income 2024

LGVN net income (TTM) was -$21.41 million for the quarter ending December 31, 2023, a -13.69% decrease year-over-year.

Longeveron Inc (LGVN) Cash Flow 2024

LGVN recorded a free cash flow (TTM) of -$19.70 million for the quarter ending December 31, 2023, a -32.86% decrease year-over-year.

Longeveron Inc (LGVN) Earnings per Share 2024

LGVN earnings per share (TTM) was -$10.20 for the quarter ending December 31, 2023, a -13.33% decline year-over-year.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.